Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J. Alvarez-Manceñido F, et al. Among authors: visa l. Gastric Cancer. 2021 Jul;24(4):926-936. doi: 10.1007/s10120-021-01169-6. Epub 2021 Mar 2. Gastric Cancer. 2021. PMID: 33651195
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F. Gomez-Martin C, et al. Among authors: visa l. J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127447
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer.
Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez Lorenzo ML, Plazas JG, Custodio A, Hernández R, Garrido M, García T, Echavarría I, Cano JM, Rodríguez Palomo A, Mangas M, Macías Declara I, Ramchandani A, Visa L, Viudez A, Buxó E, Díaz-Serrano A, López C, Azkarate A, Longo F, Castañón E, Sánchez Bayona R, Pimentel P, Limón ML, Cerdá P, Álvarez Llosa R, Serrano R, Lobera MPF, Alsina M, Hurtado Nuño A, Gómez-Martin C. Jiménez-Fonseca P, et al. Among authors: visa l. Gastric Cancer. 2017 May;20(3):465-474. doi: 10.1007/s10120-016-0639-8. Epub 2016 Sep 6. Gastric Cancer. 2017. PMID: 27599830 Free article.
On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.
Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo ML, Ramchandani A, Martínez EA, Custodio A, Garrido M, Echavarría I, Cano JM, Barreto JE, García TG, Manceñido FÁ, Lacalle A, Cardona MF, Mangas M, Visa L, Buxó E, Azkarate A, Díaz-Serrano A, Montes AF, Rivera F. Carmona-Bayonas A, et al. Among authors: visa l. J Natl Compr Canc Netw. 2016 Nov;14(11):1379-1388. doi: 10.6004/jnccn.2016.0148. J Natl Compr Canc Netw. 2016. PMID: 27799509
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.
Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Sánchez Cánovas M, Hernández R, Pericay C, Echavarria I, Lacalle A, Visa L, Rodríguez Palomo A, Mangas M, Cano JM, Buxo E, Álvarez-Manceñido F, García T, Lorenzo JE, Ferrer-Cardona M, Viudez A, Azkarate A, Ramchandani A, Arias D, Longo F, López C, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Fernández Montes A, Sala P, Cerdá P, Rivera F, Gallego J; AGAMENON study group. Carmona-Bayonas A, et al. Among authors: visa l. Gastric Cancer. 2018 Jan;21(1):96-105. doi: 10.1007/s10120-017-0718-5. Epub 2017 Apr 9. Gastric Cancer. 2018. PMID: 28393278 Free article.
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.
Custodio A, Carmona-Bayonas A, Jiménez-Fonseca P, Sánchez ML, Viudez A, Hernández R, Cano JM, Echavarria I, Pericay C, Mangas M, Visa L, Buxo E, García T, Rodríguez Palomo A, Álvarez Manceñido F, Lacalle A, Macias I, Azkarate A, Ramchandani A, Fernández Montes A, López C, Longo F, Sánchez Bayona R, Limón ML, Díaz-Serrano A, Hurtado A, Madero R, Gómez C, Gallego J. Custodio A, et al. Among authors: visa l. Br J Cancer. 2017 Jun 6;116(12):1526-1535. doi: 10.1038/bjc.2017.122. Epub 2017 May 2. Br J Cancer. 2017. PMID: 28463962 Free PMC article.
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.
Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, Echavarria I, Macias I, Mangas M, Visa L, Buxo E, Álvarez Manceñido F, Viudez A, Pericay C, Azkarate A, Ramchandani A, López C, Martinez de Castro E, Fernández Montes A, Longo F, Sánchez Bayona R, Limón ML, Diaz-Serrano A, Martin Carnicero A, Arias D, Cerdà P, Rivera F, Vieitez JM, Sánchez Cánovas M, Garrido M, Gallego J. Jiménez Fonseca P, et al. Among authors: visa l. Br J Cancer. 2017 Sep 5;117(6):775-782. doi: 10.1038/bjc.2017.245. Epub 2017 Aug 1. Br J Cancer. 2017. PMID: 28765618 Free PMC article.
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis.
Visa L, Jiménez-Fonseca P, Martínez EA, Hernández R, Custodio A, Garrido M, Viudez A, Buxo E, Echavarria I, Cano JM, Macias I, Mangas M, de Castro EM, García T, Manceñido FÁ, Montes AF, Azkarate A, Longo F, Serrano AD, López C, Hurtado A, Cerdá P, Serrano R, Gil-Negrete A, Carnicero AM, Pimentel P, Ramchandani A, Carmona-Bayonas A; AGAMENON Study Group. Visa L, et al. J Geriatr Oncol. 2018 May;9(3):254-264. doi: 10.1016/j.jgo.2017.11.008. Epub 2017 Dec 11. J Geriatr Oncol. 2018. PMID: 29242093
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry.
Carmona-Bayonas A, Jiménez-Fonseca P, Echavarria I, Sánchez Cánovas M, Aguado G, Gallego J, Custodio A, Hernández R, Viudez A, Cano JM, Martínez de Castro E, Macías I, Martín Carnicero A, Garrido M, Mangas M, Álvarez Manceñido F, Visa L, Azkarate A, Ramchandani A, Fernández Montes A, Longo F, Sánchez A, Pimentel P, Limón ML, Arias D, Cacho Lavin D, Sánchez Bayona R, Cerdá P, García Alfonso P; AGAMENON Study Group. Carmona-Bayonas A, et al. Among authors: visa l. Eur J Surg Oncol. 2018 Aug;44(8):1191-1198. doi: 10.1016/j.ejso.2018.03.019. Epub 2018 Mar 31. Eur J Surg Oncol. 2018. PMID: 29685755
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J, Sánchez-Cabús S, Laquente B, Gaba L, Visa L, Fabregat J, Povés I, Roselló S, Díaz-Beveridge R, Martín-Richard M, Rodriguez J, Sabater L, Conill C, Cambray M, Reig A, Ayuso JR, Valls C, Ferrández A, Bombí JA, Ginés A, García-Albéniz X, Fernández-Cruz L. Maurel J, et al. Among authors: visa l. Cancer Chemother Pharmacol. 2018 Dec;82(6):935-943. doi: 10.1007/s00280-018-3682-9. Epub 2018 Sep 17. Cancer Chemother Pharmacol. 2018. PMID: 30225601 Clinical Trial.
50 results